!!! OXIS - heute wieder News !!! - 500 Beiträge pro Seite
eröffnet am 12.05.06 09:40:48 von
neuester Beitrag 19.05.06 16:49:20 von
neuester Beitrag 19.05.06 16:49:20 von
Beiträge: 6
ID: 1.059.644
ID: 1.059.644
Aufrufe heute: 0
Gesamt: 742
Gesamt: 742
Aktive User: 0
ISIN: US36254L1008 · WKN: A2DWHF
0,5000
USD
+13,64 %
+0,0600 USD
Letzter Kurs 11.02.21 Nasdaq OTC
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 141,00 | +41,00 | |
| 1,1500 | +34,98 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8700 | -12,62 | |
| 12,150 | -12,72 | |
| 35,69 | -13,71 | |
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 |
Feedback
OXIS International, Inc. (OTCBB:OXIS) (Nouveau Marche:OXIS) (FWB:OXI) today announced that the Company's President and Chief Executive Officer Steve Guillen will present at the Rodman & Renshaw Third Annual Global Healthcare Conference in Monte Carlo, Monaco on Tuesday, May 16th, 2006 at 9:00 a.m. U.S. Eastern Time (3:00 p.m. Central European Time)
OXIS International is a biopharmaceutical company focused on commercializing research assays, nutraceutical and therapeutic products related to oxidative stress and, through its majority interest in BioCheck, a leading provider of high quality immunoassay clinical kits and contract services.
Rodman & Renshaw will provide a live webcast of the presentation at: http://wsw.com/webcast/rrshq8/oxis.ob/. The webcast and the presentation slides will also be archived for 90 days on the Rodman & Renshaw website and in the Investor Relations section of OXIS' web site at www.oxis.com.
Rodman & Renshaw, LLC is a privately-held, full-service investment bank focusing on emerging growth companies in the life science and technology sectors. The firm's annual healthcare conference is attended by more than 2,000 delegates and will feature over 150 emerging growth biotechnology companies in the areas of oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology.
About OXIS and BioCheck:
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress associated with damage from free radical and reactive oxygen species. The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. OXIS has acquired a 51% interest in and has the option to purchase the remaining 49% of BioCheck.
BioCheck, Inc. is a leading provider of high quality enzyme immunoassay research services and products including immunoassay kits for cardiac and tumor markers, infectious diseases, thyroid function, steroids, and fertility hormones. The company operates a 15,000 square-foot, U.S. Food and Drug Administration (FDA) certified cGMP, and ISO device-manufacturing facility in Foster City, California. BioCheck has advanced developmental programs on two promising cancer biomarkers, related to the Id-gene, and the HMGA2 gene. Id proteins play a significant role in the process of tumor related angiogenesis and other functions related to blood vessel formation. The HMGA2 gene has been implicated in aggressive forms of breast cancer.
More information about OXIS, BioCheck and its products, services as well as current SEC filings may be obtained by visiting http://www.oxis.com, http://www.oxisresearch.com and http://www.biocheckinc.com.
OXIS International is a biopharmaceutical company focused on commercializing research assays, nutraceutical and therapeutic products related to oxidative stress and, through its majority interest in BioCheck, a leading provider of high quality immunoassay clinical kits and contract services.
Rodman & Renshaw will provide a live webcast of the presentation at: http://wsw.com/webcast/rrshq8/oxis.ob/. The webcast and the presentation slides will also be archived for 90 days on the Rodman & Renshaw website and in the Investor Relations section of OXIS' web site at www.oxis.com.
Rodman & Renshaw, LLC is a privately-held, full-service investment bank focusing on emerging growth companies in the life science and technology sectors. The firm's annual healthcare conference is attended by more than 2,000 delegates and will feature over 150 emerging growth biotechnology companies in the areas of oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology.
About OXIS and BioCheck:
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress associated with damage from free radical and reactive oxygen species. The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. OXIS has acquired a 51% interest in and has the option to purchase the remaining 49% of BioCheck.
BioCheck, Inc. is a leading provider of high quality enzyme immunoassay research services and products including immunoassay kits for cardiac and tumor markers, infectious diseases, thyroid function, steroids, and fertility hormones. The company operates a 15,000 square-foot, U.S. Food and Drug Administration (FDA) certified cGMP, and ISO device-manufacturing facility in Foster City, California. BioCheck has advanced developmental programs on two promising cancer biomarkers, related to the Id-gene, and the HMGA2 gene. Id proteins play a significant role in the process of tumor related angiogenesis and other functions related to blood vessel formation. The HMGA2 gene has been implicated in aggressive forms of breast cancer.
More information about OXIS, BioCheck and its products, services as well as current SEC filings may be obtained by visiting http://www.oxis.com, http://www.oxisresearch.com and http://www.biocheckinc.com.
Antwort auf Beitrag Nr.: 21.532.965 von Hobbytrader1968 am 12.05.06 09:40:48Jetzt kommt Oxis endlich richtig ins Gespräch. Das Potenzial ist völlig unterschätzt.
Es wird scheinbar weiterhin mit kleinsten Stückzahlen gedrückt.
und heute Start mit > 8 % plus 
Guten Morgen
bin gespannt, wie's heute weitergeht. Die letzten Tage waren ja nicht berauschend
bin gespannt, wie's heute weitergeht. Die letzten Tage waren ja nicht berauschend
Trading Spotlight
Guter Start heute wieder - jetzt zahlt sich die Perle aus 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,61 | |
| -0,82 | |
| 0,00 | |
| -1,29 | |
| -0,42 | |
| -0,84 | |
| +0,41 | |
| -0,27 | |
| 0,00 | |
| -0,01 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 88 | ||
| 67 | ||
| 50 | ||
| 40 | ||
| 36 | ||
| 20 | ||
| 15 | ||
| 12 | ||
| 12 | ||
| 11 |
